^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

GOLGA4-RAF1 fusion

i
Other names: ARAF, A-Raf Proto-Oncogene, Serine/Threonine Kinase, V-Raf Murine Sarcoma 3611 Viral Oncogene Homolog 1, Serine/Threonine-Protein Kinase A-Raf, Proto-Oncogene A-Raf-1, Proto-Oncogene Pks, ARAF1, PKS2, V-Raf Murine Sarcoma 3611 Viral Oncogene-Like Protein, A-Raf Proto-Oncogene Serine/Threonine-Protein Kinase, Ras-Binding Protein DA-Raf, Proto-Oncogene A-Raf, Oncogene ARAF1, A-RAF, RAFA1, PKS, GOLGA4, Golgi Autoantigen, Golgin Subfamily A, 4, Golgin Subfamily A Member 4, Trans-Golgi P230, ProGolg
Entrez ID:
Related biomarkers:
8ms
Comprehensive Molecular Characterization of a Novel GOLGA4-RAF1 Fusion in a Pediatric Spitz Melanocytoma (ASDP 2023)
In comparison to melanomas, the rarity of this particular fusion in melanocytomas may suggest the possibility of rapid malignant transformation, and patients diagnosed with this entity should be monitored closely. Poster type: Poster Defense
Clinical • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • PRAME (Preferentially Expressed Antigen In Melanoma) • GOLGA4 (Golgin A4) • MLANA (Melan-A)
|
TMB-L • PRAME expression • GOLGA4-RAF1 fusion
1year
The spectrum of RAF1 fusion positive solid tumors in children and young adults. (ASCO 2023)
We report 8 RAF1 fusion positive solid tumors in children and young adults, mainly in low-grade gliomas. Although rare, the presence of a RAF1 fusion not only facilitates the tumor diagnosis but also provides genomic evidence for potential targeted therapies. References: 1.
Clinical
|
BRAF (B-raf proto-oncogene) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • KIAA1549 • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • GOLGA4 (Golgin A4) • TBL1XR1 (TBL1X Receptor 1)
|
KIAA1549-BRAF fusion • BRAF fusion • GOLGA4-RAF1 fusion